{"name":"Halozyme Therapeutics, Inc.","slug":"halozyme","ticker":"HALO","exchange":"NASDAQ","domain":"halozyme.com","description":"Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for m","hq":"San Diego, CA","founded":0,"employees":"423","ceo":"Helen Torley","sector":"Biotechnology / Drug Delivery","stockPrice":68.69,"stockChange":-1.34,"stockChangePercent":-1.91,"marketCap":"$8.1B","metrics":{"revenue":1508457984,"revenueGrowth":42.2,"grossMargin":76.7,"rdSpend":79048000,"netIncome":316889000,"cash":318622016,"dividendYield":0,"peRatio":24.1,"fiscalYear":"FY2020"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"PEGPH20 patent cliff ($100M at risk)","drug":"PEGPH20","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"HyQvia patent cliff ($50M at risk)","drug":"HyQvia","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Halozyme Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Halozyme reported fourth quarter and full year 2023 financial results, with revenue of $143.8 million and $532.8 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Halozyme Therapeutics Announces Collaboration with AstraZeneca to Develop and Commercialize Enhanze Technology","summary":"Halozyme entered into a collaboration with AstraZeneca to develop and commercialize its Enhanze technology for the delivery of AstraZeneca's biologics.","drugName":"","sentiment":"positive"},{"date":"2023-09-26","type":"regulatory","headline":"FDA Approves HyQvia for the Treatment of Primary Immunodeficiency","summary":"The FDA approved HyQvia for the treatment of primary immunodeficiency in patients 12 years and older.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOQndHZ2psTWVUNFJxOFd0TzdCTmRRUGh4am90RXhNQXRXMEVJbWxzTVRhWFdpTzlsMkc1WTd0X1JxNVdPemd1TDBUa0pjM0h4UnR0RmhtbGk2Uk5sSE1ZQ1BWNlRlVEpMazhwV25iRHVTNy1mMThxUmVBblp4TFlZZVduUnluYlV6VlJ4NzVQQ1ppWVZhYlJZdTVPcWZGanF4a3VQTjllUGprdTk0MEZiZlFlb1RUbE5CS2VwbWtmaXpzUThieWlwQWJPNjQyRHkxQk92S1RqamtYVGNoZmcwNS1QTjNoRXItTHNvM3hkYjFUU2ZLQm9nZmhldmlYZw?oc=5","date":"2026-04-07","type":"deal","source":"PR Newswire","summary":"Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology - PR Newswire","headline":"Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQczNMWC1kQUlTdndzQk5LQ1JDdHo3dUlGVENaZ0FGSmtwSnJQTnN2ZDg0ZUtLR2ZBVnF3T0h0a2xxVTJWYS1PTnNUNzVxdjFKc1lEZEVZQndVNnhZWWdKNHQ3RThvODdySmppUlZSUHlrUDl2V1Yzdk1KRHZPV0xSOXdueTVhbkcycGNTR2dpY2lPN3gxSy01ZGsyTDFGOThnR2xvUjZndTRhNlpsV2l1Szg2ZUVheFQtc2FkcTdn?oc=5","date":"2026-03-12","type":"pipeline","source":"PR Newswire","summary":"Halozyme Appoints David Ramsay as Interim Chief Financial Officer - PR Newswire","headline":"Halozyme Appoints David Ramsay as Interim Chief Financial Officer","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOblpmZFVVanNYQnV0azNfSWxJTHNNQXJ2aENqRmVoTGdrOU5UejRDVE42eFVWbFBNYkswR3lWdEhSZk1yaXNwaG8xYXpUbEdFQU1kVnpyc0M5aDBHdFE4OUFTWVh5bktieDZhUk9rbGRxNDBEdEJZTmJuVGJZbDUyZVY0X05PZw?oc=5","date":"2026-02-28","type":"deal","source":"Insider Monkey","summary":"12 Cheap Biotech Stocks to Buy Now - Insider Monkey","headline":"12 Cheap Biotech Stocks to Buy Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQUUx0Z2tjblZGdzBwRnhmMmFFNGtfS1JhRnRPT1UtWFJHdzdIMnNkRE1qZkgxLURWcmRkbXk3ZU52RUxla2Yzdkd1dlBkMUl6RGNxX2Q4VXZpYk1xN2hCRDRGcEhsOTJUYzl5RXNLeEdPbHd2MkpGR2V1WFYxYV9Vd2l6cUlqS1dVQkFqYXJidzhjdk9JcXRz?oc=5","date":"2026-02-18","type":"earnings","source":"Finviz","summary":"Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues - Finviz","headline":"Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNN0FqSl9vZGRBOXdWNWNqVWJ6QkdWdUVQZlFNc3Foc0ROWHBicjhZZnpwMjdnUHRzM0tZN1lsV3FwMk1kTm1BZTBQOHVBa05jQ3BEZ1EwZDVqN2NtOEJndnFzTW5LelpBZ29hMGFuOW1pbzF4eU9BQ2QzbC1QZnJEdkMtQmUwQl9XSlZUaExtSXI5R2x0Z3owdGk5YVZKbXRORy13NldNQkRYQ195?oc=5","date":"2026-02-11","type":"earnings","source":"Finviz","summary":"Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline - Finviz","headline":"Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxQLXUxZE5SZ21OY2tfYnlHeGVvVE5sOTlXOS1heXZaSl9hUGNpV05jTlhTYlJrSjRhbFNWYjN4NXQ3TmdVdDc0RUlYNXJDMFBkUURCNExkMU9pdkZPS1FGRjZFWm5ENVQtb1F4R3RUekRSb1dtN0VFNURudzNkVWh4MFNoMW5nRFl0Q24taFFtbHh6ZTF6Y2h1bHBDN2pfZFIxa3JjZkdTQ3dONWt3M1ZQb19PV3R6LTM0SXZFWFRlSVV4dkM4cEJlXzVhdXpsdUtLQ0RiRDU1SmpXVWR5TE01WnZhUzJxR0VxOHk3QV9CV1RzRllmOEJfQjRZZzJXRGdtcHF1aFJEaC1mbi1LcHY4Sg?oc=5","date":"2026-01-08","type":"deal","source":"PR Newswire","summary":"Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® - PR Newswire","headline":"Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNWjloRUNwT09LTGZFeXJtM2ExcVR2dXE4c1pXU3N0SHBrTUlFbENnTFVNTkFIOU15MHNINWo4RWZCVHR4S2lQTlBlWHMtMDVkMlZ1UmpheVJ4b0VVWEVBajNRZHpWNnZCT3pRWkt2b0RVX1BHUmRFMnYwakZmcUZYMzhyS042amNVWHRzVk1qSmw0UjRiZ2tTZGl0di03T2M4UHNZdTh4RmROVndYRzZfWXpiUQ?oc=5","date":"2026-01-05","type":"deal","source":"Contract Pharma","summary":"Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology - Contract Pharma","headline":"Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxNRDY1bFdJeFR3bjluRGtPeHAzYzhGMFFidnhSSTlOMTBSZHBZY3oxSjd5a3VlUl9SRWtIMWU5RzQzOFpGZFE2c1BiMGRsR3VhQktReUhlWjBUZmtkODJuN3pSZEtmSEUxV0pFY3hQX2JiUnc4N0F0Z2NYNkJ3dFFZdUtmM1k1QjhkUGJ6dTNjb2l2VGk3cGZwNXRiVEdnbjNTakpvQkFGZHJVLXlEU2lCVGpETTB3ZEZUeGlXY0lZeHZiWlRpaGc5QU5yQ2FxMVJDcVhsb3JpWlVPa01GNDRYbmlDWlV2dFpwZWZTWFM2TkR1TWxRU2J1WkVVOGZhRHY4blMxSGpXVEswQWRLenR4ZnljNm0zeVlBS0M4VnlDNlhTY28?oc=5","date":"2026-01-05","type":"deal","source":"PR Newswire","summary":"Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - PR Newswire","headline":"Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated wit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNVXJvbkNBZkRyNy1LOE5IUXdTRzBLWUlHQ1dKZFFFS1Yta0gtY1U0dWNxeEN6eHYyQW4yTm1qZnl4VkphUGgyeExpTVlJM0F6MzJYcWNqN1JzRmg4d2pzX0xnbDNrYlJhUzhqM2dqRUZrYldVQ0hQRnRKam1MU1FPUU5scTgtd3JRLXdhR29kNDZQaGQ1SzlDaVZWU0tHNG1lOGZEREJZMFFKc3FsWWltUlZjZ1Y5UWZCNE4tb0dQcmtJZmRkd0kxME1B?oc=5","date":"2025-12-04","type":"pipeline","source":"PR Newswire","summary":"Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany - PR Newswire","headline":"Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPN2pPM29MYWUtTC0yOHVnMEhxN0tmRGVUT1h3dm1UTmhtcFZ1em5rMG1HcGEtTmVGdXloSWRfM01sRF96VkI5TkpzR0ZNbnZQa3VqOU93dlhDa0NIWF9iNHpBSTBUTUIwVHBfb0ZpazZXby1JVFhYTl9YcFREZzZ1ZEhEdTJuNWRmWWJLaDNSME9VdDJKdTNrU0RtekJjNjBxYkkxN0M4WVU?oc=5","date":"2025-10-02","type":"deal","source":"BioSpace","summary":"Halozyme’s $900M Elektrofi Buyout Brings Two Big Pharma Partners Together - BioSpace","headline":"Halozyme’s $900M Elektrofi Buyout Brings Two Big Pharma Partners Together","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxON1BVUDMxRjgySzJkc3N0MmYtWkJSZlZKb1dDZ0xBMG5nMXh5b1JFWnRkV1ZlckRyWWliZ2FOaUF5cTBiM3VuNFFmazNSbzNrRzNIVndWNVdWcUNucjBsUU5DV1l5dDFGclJXR3luTElidkZXai11anJhRTNYcGxZWDlvWnFyTXcwQllOcko4TGVfOVNlS0xsU2xZcXl3eVhtSWZ1MlJuRVNZMU1mYTlHRw?oc=5","date":"2025-04-24","type":"pipeline","source":"Fierce Pharma","summary":"Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through - Fierce Pharma","headline":"Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPXzVqenBma1hYbmNwZHpsWktuaHBuTDFvOG5YbzA3ZGZfelV1QTdSZkdYZllXVTBFSWdwdUg3bk9sYWFIV2tYV0s4VlNaNEk3U2c0WXczdWtfZnh0bzRQT25XWE9IR2hsQVAyMWFSRHQtWHZtcVRIQkw5YU1WX2VjT2VwNmFQellSRmpxbA?oc=5","date":"2025-02-20","type":"pipeline","source":"SEC.gov","summary":"halo-20241231 - SEC.gov","headline":"halo-20241231","sentiment":"neutral"}],"patents":[{"drugName":"PEGPH20","drugSlug":"pegylated-recombinant-human-hyaluronidase","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":100000000},{"drugName":"HyQvia","drugSlug":"human-immunoglobulin-and-recombinant-human-hyaluronidase","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":50000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Sanofi","Bristol-Myers Squibb"],"therapeuticFocus":["Oncology","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":121703000,"revenuePeriod":"2020-12-31","revenueHistory":[{"value":121703000,"period":"2020-12-31"},{"value":65316000,"period":"2020-09-30"},{"value":55221000,"period":"2020-06-30"},{"value":25354000,"period":"2020-03-31"},{"value":53665000,"period":"2019-12-31"}],"grossProfit":1167837000,"grossProfitHistory":[{"period":"2025-12-31","value":1167837000},{"period":"2024-12-31","value":855907000},{"period":"2023-12-31","value":636892000},{"period":"2022-12-31","value":520812000}],"rdSpend":79048000,"rdSpendHistory":[{"period":"2025-12-31","value":81490000},{"period":"2024-12-31","value":79048000},{"period":"2023-12-31","value":76363000},{"period":"2022-12-31","value":66607000}],"sgaSpend":207092000,"operatingIncome":802593000,"operatingIncomeHistory":[{"period":"2025-12-31","value":802593000},{"period":"2024-12-31","value":551475000},{"period":"2023-12-31","value":337574000},{"period":"2022-12-31","value":267531000}],"netIncome":316889000,"netIncomeHistory":[{"period":"2025-12-31","value":316889000},{"period":"2024-12-31","value":444091000},{"period":"2023-12-31","value":281594000},{"period":"2022-12-31","value":202129000}],"eps":2.56,"epsHistory":[{"period":"2025-12-31","value":2.56},{"period":"2024-12-31","value":3.43},{"period":"2023-12-31","value":2.1},{"period":"2022-12-31","value":1.44}],"cash":133820000,"cashHistory":[{"period":"2025-12-31","value":133820000},{"period":"2024-12-31","value":115850000},{"period":"2023-12-31","value":118370000},{"period":"2022-12-31","value":234195000}],"totalAssets":2525323000,"totalLiabilities":2476509000,"totalDebt":2142630000,"equity":48814000,"operatingCashflow":651558000,"operatingCashflowHistory":[{"period":"2025-12-31","value":651558000},{"period":"2024-12-31","value":479064000},{"period":"2023-12-31","value":388571000},{"period":"2022-12-31","value":240110000}],"capex":-294741000,"capexHistory":[{"period":"2025-12-31","value":-294741000},{"period":"2024-12-31","value":-10696000},{"period":"2023-12-31","value":-15294000},{"period":"2022-12-31","value":-4810000}],"freeCashflow":356817000,"dividendsPaid":null,"buybacks":-342372000,"employees":423,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":77028000,"ebit":-95938000,"ebitda":-69258000,"period":"2025-12-31","revenue":451767000,"epsBasic":-1.2,"netIncome":-141591000,"rdExpense":31897000,"epsDiluted":-1.2,"grossProfit":372997000,"operatingIncome":240696000},{"sga":46088000,"ebit":223254000,"ebitda":243674000,"period":"2025-09-30","revenue":354264000,"epsBasic":1.49,"netIncome":175225000,"rdExpense":17251000,"epsDiluted":1.43,"grossProfit":299022000,"operatingIncome":217921000},{"sga":41614000,"ebit":209332000,"ebitda":229834000,"period":"2025-06-30","revenue":325719000,"epsBasic":1.36,"netIncome":165160000,"rdExpense":17543000,"epsDiluted":1.33,"grossProfit":279360000,"operatingIncome":202441000},{"sga":42362000,"ebit":148353000,"ebitda":168802000,"period":"2025-03-31","revenue":264861000,"epsBasic":0.96,"netIncome":118095000,"rdExpense":14799000,"epsDiluted":0.93,"grossProfit":216458000,"operatingIncome":141535000},{"sga":42249000,"ebit":182754000,"ebitda":203169000,"period":"2024-12-31","revenue":298008000,"epsBasic":1.08,"netIncome":137012000,"rdExpense":20441000,"epsDiluted":1.06,"grossProfit":255953000,"operatingIncome":175501000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":68.69,"previousClose":70.03,"fiftyTwoWeekHigh":82.22,"fiftyTwoWeekLow":47.74,"fiftyTwoWeekRange":"47.74 - 82.22","fiftyDayAverage":65.6,"twoHundredDayAverage":68.84,"beta":0.88,"enterpriseValue":10132485120,"forwardPE":7,"priceToBook":37.07,"priceToSales":5.4,"enterpriseToRevenue":6.72,"enterpriseToEbitda":10.63,"pegRatio":0,"ebitda":953009984,"ebitdaMargin":63.2,"freeCashflow":228120752,"operatingCashflow":677414976,"totalDebt":2144638976,"debtToEquity":976.5,"currentRatio":2.76,"returnOnAssets":22.1,"returnOnEquity":99.4,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":9,"targetMeanPrice":85.44,"targetHighPrice":96,"targetLowPrice":57,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.1,"institutionHeldPercent":109.9,"sharesOutstanding":118613000,"floatShares":117297582,"sharesShort":14381741,"shortRatio":10.27,"shortPercentOfFloat":12.1,"epsTrailing":2.85,"epsForward":9.84,"revenuePerShare":12.72,"bookValue":1.85,"officers":[{"age":62,"name":"Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.","title":"President, CEO & Director"},{"age":48,"name":"Ms. Cortney  Caudill M.B.A.","title":"Senior VP & COO"},{"age":57,"name":"Mr. Mark  Snyder Esq.","title":"Senior VP, General Counsel, Chief Compliance Officer & nd Secretary"},{"age":60,"name":"Mr. David A. Ramsay MBA","title":"Interim Chief Financial Officer"},{"age":null,"name":"Ms. Tram  Bui","title":"Head of Investor Relations & Corporate Communications"},{"age":null,"name":"Dr. Christopher  Wahl M.B.A., M.D.","title":"Chief Scientific Officer"},{"age":61,"name":"Dr. Charles P. Theuer M.D., Ph.D.","title":"Chief Medical Officer"},{"age":56,"name":"Mr. Paul  Spence","title":"Chief Commercial Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://halozyme.com","phone":"858 794 8889"}}